Prognosis, imatinib dose, and benefit of sunitinib in GIST: knowing the genotype.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. Molecular Mechanisms and Clinical Implications ofCurrent issues in molecular biology · 2025
   Review
2. Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumor After Imatinib Resistance.Pharmaceutics · 2025
   Review
3. Emerging Targeted Therapeutic Strategies to Overcome Imatinib Resistance of Gastrointestinal Stromal Tumors.International journal of molecular sciences · 2023
   Review
4. Managing sarcoma: where have we come from and where are we going?Therapeutic advances in medical oncology · 2017
   Review
5. Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives.OncoTargets and therapy · 2016
   Review
6. The KIT Exon 11 Stop Codon Mutation in Gastrointestinal Stromal Tumors: What Is the Clinical Meaning?Gut and liver · 2013
   Article
7. Analysis of a case with disappearance of the primary gastrointestinal stromal tumor and progressive liver metastases under long-term treatment with tyrosine kinase inhibitors.Medical oncology (Northwood, London, England) · 2010
   Article
8. Role of imatinib in the management of early, operable, and advanced GI stromal tumors (GISTs).OncoTargets and therapy · 2009
   Article

Corrections and comments

• Comment on
  Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.2008

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as